Issue 1, 2017

Antimalarial drug discovery targeting apical membrane antigen 1

Abstract

Malaria continues to frustrate humanity's attempts to eradicate this deadly disease. Although gains have been made over the last 15 years, drug resistance to malaria continues to be a major concern. The lack of new antimalarials with novel mechanisms of action continues to challenge the scientific community to find innovative targets to combat this persistent disease. One such target, apical membrane antigen 1 (AMA1), is an essential protein that helps the parasite invade host erythrocytes. Recently, a number of efforts have focused on the druggability of this target, aiming to block the interactions of AMA1 that mediate invasion of host cells. This review covers recent progress in drug discovery targeting this crucial protein–protein interaction in malaria.

Graphical abstract: Antimalarial drug discovery targeting apical membrane antigen 1

Article information

Article type
Review Article
Submitted
31 Aug 2016
Accepted
27 Oct 2016
First published
04 Nov 2016

Med. Chem. Commun., 2017,8, 13-20

Antimalarial drug discovery targeting apical membrane antigen 1

S. M. Devine, C. A. MacRaild, R. S. Norton and P. J. Scammells, Med. Chem. Commun., 2017, 8, 13 DOI: 10.1039/C6MD00495D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements